| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Aurora Cannabis Inc. Common Shares$2.93
+0.01 (+0.34%)
F 10Pipeline Score Tools & Services · Pre-Clinical
Market Cap
194.51 M
EPS
-1.15
P/E Ratio
-2.99 $
Value Trade
1.63 M
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
1.61 M
52 Week Range
3.07 - 6.67
% held by Insiders
0.54 %
% held by Institutions
9.57 %
Enterprise Value
178.51 M
Total Shares
56.69 M
Short %
11.93 %
Float Shares
56.43 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F10
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 9%
Micro Cap (rank 825 of 905)
Percentile RankAurora Cannabis Inc. Common Shares has significant pipeline risk (10/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ACB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ACB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ACB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ACB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ACB Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ACB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-ACB
Jun 11, 2026Aurora Cannabis Announces Full Year and Fiscal 2026 Fourth Quarter Results with Record Annual Revenue and Adjusted EBITDA¹
Aurora Cannabis reported record annual revenue of $288.6 million for fiscal year 2026, marking an 18% year-over-year growth. The company also achieved an adjusted EBITDA of $53.8 million, a 32% increase from the previous year. Despite these successes, Aurora faced a net loss of $27.6 million in Q4 2026, attributed to increased expenses and strategic shifts away from the consumer cannabis market. The acquisition of Safari Flower Company is expected to bolster Aurora's capacity in profitable international markets.
Read more →-ACB
Jun 2, 2026Aurora Deepens its Impact for Veterans Across Canada
Aurora Cannabis Inc. is enhancing its support for Veterans in Canada through its Strains for Heroes program, which donates a portion of profits to Veteran-focused organizations. Recent contributions include support for food security, mental health initiatives, and community engagement. The company emphasizes its commitment to understanding and addressing the needs of Veterans.
Read more →-ACB
May 28, 2026Aurora Cannabis to Host Fourth Quarter and Fiscal Year 2026 Investor Conference Call and File Related Year End Information
Aurora Cannabis Inc. has announced a conference call scheduled for June 11, 2026, to discuss its fourth quarter and fiscal year 2026 financial results. The call will be hosted by CEO Miguel Martin and CFO Simona King, following the release of the financial statements. The company continues to emphasize its commitment to patient care and global expansion in the medical cannabis sector.
Read more →-ACB
May 14, 2026Aurora Granted Plant Breeders' Rights, Strengthening Leadership in Cannabis Science
Aurora Cannabis Inc. has been granted Plant Breeders' Rights in Canada for two proprietary cannabis cultivars, Farm Gas™ and Driftwood Diesel™, developed at its research facility in Comox, British Columbia. This certification provides Aurora exclusive rights to grow and sell products from these varieties, enhancing its global competitive position. The rights recognize the company's significant investment in breeding and genetic development.
Read more →-ACB
Apr 15, 2026Aurora Cannabis Accelerates Global Medical Cannabis Leadership with Accretive Acquisition of Safari Flower Company, Expanding EU GMP Capacity to Serve Growing High Margin International Markets
Aurora Cannabis has acquired Safari Flower Company for $26.5 million, enhancing its EU GMP capacity. This acquisition is aimed at expanding its supply of high-quality cannabis to international markets, including Germany and Australia. The deal is expected to contribute positively to Aurora's financial performance starting in fiscal year 2027.
Read more →-ACB
Mar 30, 2026Aurora Recognized for Executive Gender Diversity by the Globe & Mail for Second Consecutive Year
Aurora Cannabis Inc. has been recognized by The Globe and Mail for the second consecutive year in its Report on Business Women Lead Here list, highlighting the company's commitment to gender diversity at the executive level. With 50% female leadership, Aurora emphasizes a culture of respect and accountability, fostering an environment for female leaders to thrive. This recognition underscores the company's dedication to inclusive leadership and meaningful contributions to the cannabis industry.
Read more →Competitive Position
How ACB ranks across every disease it competes inCompetitive Position is a premium feature
See how ACB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial